Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-centre study Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Use of bosentan for the treatment of pulmonary arterial hypertension in Spain: a multicenter, retrospective, observational study Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017
Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010
Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study Source: Eur Respir J, 50 (1) 1601708; 10.1183/13993003.01708-2016 Year: 2017
Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Retrospective observational study of pulmonary hypertension patients dosed with greater than 9 breaths qid of inhaled treprostinil Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil" Year: 2009
Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal Source: International Congress 2017 – PAH and CTEPH Year: 2017
Exercise tolerability in children with pulmonary arterial hypertension (PAH), a population pk/pd assessment of the effects of sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012